FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma November 18, 2026
Positive QoL Data for LYMPHIR® (denileukin diftitox-cxdl) in R/R Cutaneous T-Cell Lymphoma Presented November 11, 2026
Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Broader Pipeline November 4, 2026
Efficacy Data presented from Ph 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy October 20, 2026
FDA cleared IND application for LB2501 for R/R B-cell malignancies, including B-cell NHL October 20, 2026
Epcoritamab + R-CHOP Demonstrates Statistically Significant PFS Improvement in Patients with 1L DLBCL October 14, 2026
Epcoritamab + R-CHOP combo Demonstrates Significant PFS Improvement versus R-CHOP in 1L DLBCL Patients October 6, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences October 6, 2026
Lunsumio-based regimen significantly improves PFS in follicular lymphoma in Ph 3 CELESTIMO study September 22, 2026
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in LBCL August 25, 2026
FDA clears IND application for C-CAR039 (Prizloncabtagene Autoleucel or Prizlon-cel) for the treatment of R/R LBCL August 20, 2026
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma August 11, 2026
FDA RMAT Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as 1L Consolidation Therapy for LBCL August 5, 2026
First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell NHL July 28, 2026
FAILED TRIAL: Ph 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Patients with R/R DLBCL failed to meet primary OS endpoint July 28, 2026
Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting July 28, 2026
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers July 15, 2026
Positive Ph 3 Results for Epcoritamab + Lenalidomide in R/R DLBCL Patients Demonstrated Statistically Significant PFS Improvement July 7, 2026
TEPKINLY (epcoritamab) in Combination with Lenalidomide & Rituximab Approved by the European Commission for the Treatment of R/R Follicular Lymphoma July 7, 2026
Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities Announced June 30, 2026